2023
The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership
Snyder R, Burtness B, Cho M, Del Rivero J, Doroshow D, Hitchcock K, Kalyan A, Kim C, Lukovic J, Parikh A, Sanford N, Singh B, Shen C, Shroff R, Vijayvergia N, Goodman K, Kunz P. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership. Journal Of The National Cancer Institute 2023, 115: 1132-1138. PMID: 37364007, PMCID: PMC11009492, DOI: 10.1093/jnci/djad121.Peer-Reviewed Original ResearchConceptsNational Clinical Trials NetworkTrial leadershipClinical Trials NetworkDesign of trialsNational Cancer InstituteTask ForceCancer careClinical trialsNovel therapiesGastrointestinal oncologyCancer InstituteTrials NetworkMultidisciplinary investigatorsTrialsCooperative groupsBroader populationCancer researchOncology
2015
EGFR-directed antibodies increase the risk of severe infection in cancer patients
Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSevere infectionsMonoclonal antibodiesRole of EGFRDose modification strategiesMonoclonal antibody treatmentClinical trial designRisk of infectionPractice of oncologyGrowth factor receptorConstitutional symptomsAntibody treatmentHypersensitivity reactionsCancer patientsRadiation therapyTrial designSolid tumorsInfection riskInfectionFactor receptorAntibodiesFurther studiesPatientsRiskRelated articles
2014
On mentorship: lessons from my father.
Burtness B. On mentorship: lessons from my father. Journal Of The National Comprehensive Cancer Network 2014, 12: 1651-2. PMID: 25361809, DOI: 10.6004/jnccn.2014.0162.Peer-Reviewed Original ResearchTargeted agents: management of dermatologic toxicities.
Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsDermatologic side effectsQuality of lifeDermatologic toxicitiesCutaneous complicationsSkin complicationsTherapeutic mainstayReceptor inhibitorsCommon culpritsToxicity profileMTOR inhibitorsSide effectsCosmetic issuesAnticancer treatmentPotential infectionComplicationsTreatmentInhibitorsTherapyAgentsCancerInfectionMainstayBRAF
2013
Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I. Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation. Cancer Discovery 2013, 3: 96-111. PMID: 23125191, PMCID: PMC3546138, DOI: 10.1158/2159-8290.cd-12-0031.Peer-Reviewed Original ResearchConceptsEGF receptorPathway genesDegradation of EGFROncogenic EGF receptorEGF receptor degradationBiosynthesis pathway genesPlatelet-derived growth factor receptorEndocytic traffickingVesicular traffickingEGF receptor inhibitorEGFR degradationDimerization partnerBioinformatics modelingGrowth factor receptorUnexpected roleReceptor degradationCancer cell viabilityNSDHLSC4MOLCholesterol pathwayGenesFactor receptorCancer resistanceEGFR antagonistsCancer cells
2012
Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”
Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”. Science Signaling 2012, 5: lc5. PMID: 23233526, DOI: 10.1126/scisignal.2003734.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorGrowth factor receptorToll-like receptor 3Functional innate immune responseFactor receptorInnate immune responseFulminant infectionCombination therapyImmune responseTumor growthReceptor 3Mammalian targetCancer therapeuticsReceptorsMTORPatientsBody of literatureTherapyTumorsInfection
2005
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Of Today 2005, 41: 107-27. PMID: 15821783, DOI: 10.1358/dot.2005.41.2.882662.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibody SpecificityAntineoplastic AgentsApoptosisArea Under CurveCell ProliferationCetuximabChemotherapy, AdjuvantClinical Trials as TopicDrug Resistance, NeoplasmErbB ReceptorsHalf-LifeHumansNeoplasmsNeovascularization, PathologicRadiation ToleranceConceptsEpidermal growth factor receptorImportant clinical prognostic markerHydrophobic transmembrane regionCell cycle progressionIntracellular tyrosine kinaseLigand-binding domainNormal human cellsProtein phosphorylationTransmembrane regionCytoplasmic regionGene transcriptionGrowth factor receptorEndogenous ligandCycle progressionExtracellular domainTyrosine kinaseOverall downregulationHuman cellsConformational changesNew anticancer therapiesHuman tumor cell linesErbB familyTumor cell linesVariety of cancersFactor receptor
2003
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology 2003, 10: 132-139. PMID: 12673177, DOI: 10.1067/mnc.2003.7.Peer-Reviewed Original ResearchConceptsCongestive heart failureDoxorubicin therapyBaseline LVEFHeart failureCumulative doxorubicin doseLower baseline LVEFNormal baseline LVEFCancer-related deathCancer chemotherapeutic agentsLVEF monitoringLower LVEFDoxorubicin doseCardiac functionDoxorubicin chemotherapySerious toxicityLower incidenceEquilibrium radionuclideLVEFHigh incidenceERNA studiesAdditional casesChemotherapeutic agentsCancer typesPatientsTherapy
2002
Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer
Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I Dose Escalation Trial of Weekly Docetaxel Plus Irinotecan in Patients with Advanced Cancer. Cancer Biology & Therapy 2002, 1: 646-651. PMID: 12642688, DOI: 10.4161/cbt.314.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityWeek of restWeekly docetaxelPancreatic cancerDose levelsSolid tumorsPredominant dose-limiting toxicityCommon dose-limiting toxicityNon-small cell lungPhase II dosesNausea/vomitingAdvanced solid tumorsMaximum-tolerated dosePhase II trialPhase I trialNonhematologic toxicityEligible patientsEscalation trialII trialPartial responseSevere neutropeniaWeekly administrationI trialAdvanced cancerCell lungPhase I Study of Perillyl Alcohol in Patients with Refractory Malignancies
Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy 2002, 1: 130-135. PMID: 12170772, DOI: 10.4161/cbt.57.Peer-Reviewed Original ResearchConceptsPeak plasma concentrationPlasma concentrationsChronic basisDihydroperillic acidMean peak plasma concentrationLow-grade nauseaPerillyl alcoholStabilization of diseaseGastrointestinal side effectsH post ingestionPerillic acidMonoterpene perillyl alcoholStarting doseRefractory malignanciesPost ingestionSide effectsPatientsMajor metabolitePharmacokinetic studyDoseMicroMNauseaMalignancyAverage numberDisease
2000
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
Murren J, Peccerillo K, DiStasio S, Li X, Leffert J, Pizzorno G, Burtness B, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577, DOI: 10.1007/s002800000115.Peer-Reviewed Original ResearchConceptsDose of irinotecanElimination of irinotecanDrug AdministrationAdvanced cancerFirst cycle patientsChemotherapy-related toxicityDose of paclitaxelClinical side effectsSequence of administrationBlood cell elementsNonhematologic toxicityReversible neutropeniaFirst doseMost patientsPartial responseCycle patientsDose escalationMild diarrheaPreclinical dataPlasma concentrationsSide effectsIrinotecanPatientsPharmacokinetic parametersWeekly scheduleA phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.
Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. The Cancer Journal 2000, 6: 309-15. PMID: 11079170.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityRest weekNovel antimetaboliteWeekly scheduleHuman tumor xenograft modelsWeeks of therapyLife-threatening toxicityPhase I trialFrequent dosing scheduleTumor xenograft modelIndicator lesionsNoninfectious feverPersistent neutropeniaStable diseaseWeekly infusionsDose escalationDosing schedulesI trialRectal cancerAdvanced cancerInitial doseMonths durationXenograft modelPatientsPreclinical tests
1997
Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal Of Clinical Oncology 1997, 15: 148-57. PMID: 8996136, DOI: 10.1200/jco.1997.15.1.148.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMaximum-tolerated doseMg/ m2/dDose of topotecanM2/dRefractory cancerDay 1Treatment cyclesDrug-induced DNA fragmentationGrowth factor supportTransfusion of RBCsDose of cyclophosphamideFirst treatment cycleAdministration of cyclophosphamideGranulocyte colony-stimulating factorPharmacokinetics of topotecanClass of agentsColony-stimulating factorBlood cell elementsBolus scheduleNonhematologic toxicityReversible neutropeniaDNA fragmentationFactor supportCombination therapy